Skip to Content
Canadian Paediatric Society

Position statement

Using probiotics in the paediatric population

Posted: Dec 3 2012 | Reaffirmed: Feb 28 2015

The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.

Principal author(s)

Valérie Marchand; Canadian Paediatric Society, Nutrition and Gastroenterology Committee

Abridged version: Paediatr Child Health 17(10):575


As more is learned about the importance of the intestinal microbiome to human health there is increasing interest in the potential benefits of probiotics. Probiotics are live micro-organisms which, when consumed in adequate amounts, confer a health effect on the host by altering its microflora. Probiotics have been administered both prophylactically and therapeutically for various conditions. This statement definines the development and role of intestinal microflora, and examines the evidence supporting the use of different probiotics to treat common paediatric conditions, such as diarrhea, atopy, functional intestinal disorders and necrotizing enterocolitis. Recommendations to guide physicians in the judicious use of these products are offered.

Key Words: Bifidobacteria; Diarrhea; Lactobacilli; Microflora; Probiotics; Saccharomyces 


This statement defines what probiotics and prebiotics are, reviews the development and role of intestinal microflora and examines evidence supporting the use of different probiotics for various childhood conditions. A literature review was conducted in English and French using Medline (1966 to 2011), the Cochrane database and relevant websites. PubMed was used to identify relevant randomized controlled trials (RCTs) and meta-analyses involving the use of probiotics in paediatrics. Physician guidance for the judicious use of these products in paediatric patients is offered.

Probiotics (eg, lactobacilli, bifidobacteria, saccharomyces) are live micro-organisms which can confer a health effect on the host when consumed in adequate amounts. They are nonpathogenic in the normal host, resist processing and are able to survive in the digestive tract. Prebiotics (eg, fructo- and galacto-oligosaccharides) are nonviable food components which can confer a health benefit on the host by modulating intestinal microflora.

Development and composition of gut microflora

Colonization of an infant’s intestine begins immediately after birth. Type of delivery, the infant diet (breast milk versus formula) and other factors, such as environment, gestational age and the presence of antibiotics, influence the composition of gut microflora. Because bifidobacteria and galacto-oligosaccharides are components of breast milk, the flora of breastfed infants contain more lactobacilli and bifidobacteria than the flora of formula-fed infants. Once solid food is introduced into the diet, the composition of a child’s intestinal microflora begins to resemble the adult flora.

The role of gut microflora

The gut microflora is a complex ecosystem supporting the structure and function of the intestinal mucosa. Intestinal bacteria contribute to the gut’s barrier function by competing with pathogenic bacteria, increasing mucin secretion, decreasing gut permeability and modulating the gut’s immune function.[1][3]Colonic bacteria metabolize malabsorbed carbohydrates into short-chain fatty acids (SCFA). SCFA are a preferential fuel for the enterocyte; they also acidify colonic content and increase water absorption.

Using probiotics

Probiotics modify the gut microflora by lowering colonic pH through production of SCFA, by producing antimicrobial compounds and antitoxins, and by competing with other bacteria for nutrients and adhesion receptors. They also enhance gut barrier function and have a role in immunomodulation. Different strains of probiotics have different biological activities.

Preventing antibiotic-associated diarrhea

Antibiotic-associated diarrhea (AAD) is usually defined as ≥3 loose stools/day for ≥2 days occurring up to two weeks after the initiation of antibiotics. AAD occurs in about 30% of patients.

A 2002 meta-analysis which included two paediatric and seven adult studies favoured the use of probiotics, with an OR of 0.37.[4] Several paediatric RCTs using different strains of probiotics were also published [5][12](Table 1), as well as two specifically paediatric meta-analyses, which showed a significant reduction of AAD using various probiotics (RR 0.47 and 0.44). The most consistently effective were Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii. However, the number needed to treat to prevent one case of diarrhea was 10 in one meta-analysis and seven in the other.[13][14] Consuming yogurt containing probiotics did not prevent AAD in another study.[15]

While per protocol results seem to indicate that probiotics such as S boulardii and LGG decrease the incidence of AAD, the intention to treat analysis showed less impressive results, suggesting that lack of compliance may be an issue.

Random controlled trials of probiotic use for preventing AAD


Patient number, age range



Tankanow, 1990[12]

(5 mos to 6 yrs)

L acidophilus

L bulgaricus

RR 0.96 (NS)

Arvola, 1999[8]

167 (119)†
(2 wks to 12.8 yrs)

2x1010 CFU twice daily

Probiotic 5%
Placebo 16%
RR 0.32 (NS)

Vanderhoof, 1999[7]

202 (188)
(6 mos to 10 yrs)

1 – 2x1010 CFU daily

Probiotic 8%

Placebo 26%

RR 0.29 *

Jirapinyo, 2002[11]

(1 to 36 mos)

L acidophilus

B infantis

Probiotic 37%
Placebo 80%
RR 0.47 (NS)

Kotowska, 2004[5]

269 (246)
(6 mos to 14 yrs)

S boulardii
250 mg twice/day

Probiotic 7.5%
Placebo 23%
RR 0.30 *

Erdeve, 2004[6]


S boulardii

Probiotics 5.7%
Placebo 18.9%
RR 0.30*

Correa 2005[10]

169 (157)
(6 mos to 36 mos)

B lactis|
1x107 CFU/g of powder

S thermophilus
1x106 CFU/g of powder

Probiotics 16%
Placebo 31%
RR 0.52 *

Ruszczynski, 2008[9]

(3 mos to 14 yrs)

L rhamnosus (strains E/N, Oxy and Pen)

Probiotic 2.5%
Placebo 7.5%
RR 0.33*

NS: non-significant, * : p < 0.05 CFU Colony forming unit, † Brackets indicate final study population

Clostridium difficile

One adult study showed a 50% decrease in the relapse rate in patients with recurrent C difficile when treated with S boulardii in conjunction with antibiotics, but no benefit for those with an initial episode.[16] An adult meta-analysis found no evidence to support the use of probiotics in the treatment of C difficile.[17] To date there have been no paediatric RCTs.

While there is currently no evidence to support using probiotics either to prevent or treat C difficile in children or adults, there might be a role for probiotics in preventing relapse in patients with recurrent C difficile infection.

Treatment of acute infectious diarrhea in children

Probiotics have been used to treat acute viral diarrhea in children. Five paediatric meta-analyses showed reduced durations of diarrhea, ranging between -16.8 h and -30.0 h.[18][22] The subgroup with rotaviral diarrhea seemed to be more responsive to probiotics[19] and LGG appeared to be the most effective probiotic [5][12](Table 2).

While probiotics are useful in reducing the duration of acute infectious viral diarrhea, efficacy is strain- and dose-dependant. The beneficial effects of probiotics seem to be more evident when treatment is initiated early (<48 h). Probiotics are not useful for treating bacterial diarrhea.

Meta-analyses: Probiotics for treatment of acute infectious diarrhea


Trials (patients)



Szajewska, 2001[26]

8 (731) (incidence)

8 (773) (duration)

LGG (3)
L reuteri (2)
L acidophilus (2)
S boulardii (1)

Diarrhea >3 days
RR 0.43 *

Duration of diarrhea
-18.2 h *

Van Niel, 2002[22]

3 (122) (no. stools)

7 (675) (duration)

LGG (4)
L reuterii (2)
L acidophilus (3)

No. stools on day 2
- 1.6 *

Duration of diarrhea
-16.8 h *

Huang, 2002[21]

18 (1917)

LGG (9)
L rhamnosus + L reuteri (2)
L acidophilus + L bulgaricus (1)
L acidophilus + B infantis (1)
L acidophilus (2)
L rhamnosus (1)
L reuteri (2)

Duration of diarrhea
-19.2 h *

Allen, 2004[19]

15 (1341) (diarrhea >3 day)

12 (duration)
(included adults and children)

LGG (2)
L reuteri (2)
Enterococcus LAB SF68 (5)
L acidophilus + L bifidus (2)
S thermophilus + L bulgaricus (1)
L acidophilus (2)
S boulardii (1)

Diarrhea >3 days
RR 0.66 *

Duration of diarrhea
-30.5 h *

Allen 2010[18]

63 (8014)
adults and children


Duration of diarrhea
-24.8 h*

NS: non-significant, * : p < 0.05

Preventing infectious diarrhea

The efficacy of probiotics in preventing infectious diarrhea has been studied in multiple settings (with hospitalized patients, in child care settings and in the community) using various strains of probiotics. LGG reduced the incidence of acute diarrhea, particularly in non-breastfed infants [23]-[26] as did S boulardii, Bifidobacterium bifidum, Lactobacillus casei, Bifidobacterium lactis, and Lactobacillus reuteri in other individual studies.[27]-[31] A combination of Bifidobacterium breve and Streptococcus thermophilus decreased the incidence of dehydration.[32] Other studies did not show a significant decrease in the incidence of acute diarrhea [33]-[34](Table 3).

There seems to be a modest effect for some probiotic strains in preventing acute diarrhea, particularly in children who are not breastfed. Probiotic use may be considered in long-term facilities or for patients attending child care who have recurrent infections.

Random controlled trials: Probiotics for prevention of infectious diarrhea


Patients (pts), age, setting, study duration



Saavedra, 1994[28]

(5 to 24 mos)
chronic medical care
duration 17 mos

B bifidum

S thermophilus

Incidence of diarrhea
Probiotics 7%
Placebo 31% *

Oberhelman, 1999[25]

(6 mos to 24 mos)
poor rural area in Peru
duration 15 mos


3.7x1010 CFU daily,
6 days/wk

Diarrhea episodes (all pts)
Probiotics 5.21/child/yr
Placebo 6.02/child/yr *
Non-breastfed infants
Probiotics 4.69/child/yr
Placebo 5.86/child/yr*
Breastfed infants
Probiotics 6.59/child/yr
Placebo 6.32/child/yr (NS)

Pedone, 2000[29]

928 (779)†
(6 mos to 24 mos)
duration 4 mos

L casei

Incidence of diarrhea
Probiotic milk 15.9%
Yogurt 22% *

Hatakka, 2001[23]

571 (513)
(1 yr to 6 yrs)
duration 7 mos


5 – 10x105 CFU/mL of formula,
> 200 mL/daily

Days with gastrointestinal symptoms
Probiotics 2.9
Placebo 3.0 (NS)

Szajewska, 2001[26]

(1 to 36 mos)
hospitalized (acute care)


6x109 CFU twice daily

Nosocomial diarrhea
Probiotics 6.7 %
Placebo 33.3% *
RR 0.2

Mastretta, 2002[24]

269 (220)
(1 to 18 mos)
hospitalized (acute care)


1x1010 CFU daily

Nosocomial rotavirus (27.7%)
Probiotics 25.4%
Placebo 30.2% (NS)
Breastfed 10.6 %
Formula fed 32.4 % *

Chouraqui, 2004[33]

(< 8 mos)
residential care setting
duration 4 mos

B lactis (Bb 12)

1x106 CFU/g of powder (formula)

Incidence of diarrhea
Probiotics 28.3%
Placebo 38.7% (NS)
Days with diarrhea
Probiotics 1.15
Placebo 2.3 *

Thibault, 2004[32]

971 (913)
(4 to 6 mos)
duration 5 mos

B breve (C50)

S thermophilus 065

Incidence of diarrhea
Probiotics 56.7%
Placebo 55.9% (NS)
Probiotics 2.5 %
Placebo 6.1% *

Weizman, 2005[30]

201 (194)
(4 to 10 mos)
child care centre
duration 12 wks

B lactis (Bb12)

L reuteri
1x107 CFU/g of powder (formula)

Episodes of diarrhea
B lactis 0.13
L reuteri 0.02
Placebo 0.31 *

Billoo, 2006[27]

(2 mos to 12 yrs)
duration 2 mos

S boulardii
250 mg twice daily

Episodes of diarrhea
Probiotic 0.32
Placebo 0.56*

Binns, 2007[31]

496 (315)
(1 yr to 3 yrs)
child care centre
duration 5 mos

B lactis and prebiotics
(CUPDAY milk)

RR 0.8 *

Chouraqui, 2008[34]

284 (227)
duration 4 mos

B longum (BL999)

L rhamnosus (LPR)

L paracasei (ST11)

BL999 + LPR 6%
BL999 + LPR + ST11 4%
Placebo 5% (NS)

NS: non-significant, * : p < 0.05 CFU Colony forming unit, † Brackets indicate final study population

NTT number needed to treat

Irritable bowel syndrome

Alteration of the gut microflora may be implicated in the pathogenesis of irritable bowel syndrome (IBS). It is a common problem in children and treatment options are limited.

Two adult meta-analyses using various strains of probiotics found a modest improvement in symptoms.[35][36] There have been four published paediatric trials. LGG decreased abdominal distension [37] and was more likely to improve symptoms of patients with IBS than a placebo.[38] Escherichia coli decreased gassiness and bloating, and one product, VSL#3 (Seaford Pharmaceuticals, Ontario), improved IBS scores [39][40](Table 4).

The data on IBS and probiotics are preliminary but there seems to be an effect in improving some symptoms.

Probiotic use in irritable bowel syndrome (IBS)

Patients, study duration



64 (50)†
Irritable bowel syndrome
Duration 6 wks


1x1010 CFU twice daily

Improved abdominal pain
Probiotic 44 %
Placebo 40% (NS)

Improved abdominal distension
Probiotic 24%
Placebo 0%*

112 (104)
Irritable bowel syndrome
Functional dyspepsia
Functional abdominal pain
Duration 4 wks


3x109 CFU twice daily

Treatment success (no pain)
Probiotic 25%
Placebo 9.6%*

Irritable bowel syndrome
Duration 43 days

E coli

1.5-4.5 x 107 CFU

Improvement of gassiness and bloating*

irritable bowel syndrome
6 wks, crossover

VSL # 3

Improvement of the IBS score (SGAR) at 6 wks
Placebo -0.51
Probiotic -1.7*

NS: non-significant, * : p < 0.05, † Brackets indicate final study population
CFU Colony forming unit; NTT Number needed to treat; SGAR Subject’s global assessment of relief

Infantile colic

The intestinal microflora may play a role in pathogenesis of colic. Lower counts of lactobacilli have been found in the intestinal flora of colicky infants.[41][42] Two trials showed a significant reduction of crying in infants receiving L reuteri [43][44](Table 5).

While there may be a role for probiotics in treating infantile colic, there is insufficient evidence to recommend for or against using probiotics to manage this condition. A recent CPS practice point on infantile colic reached the same conclusion.

Probiotic use for infantile colic


Patients, age, study duration



Savino, 2010[44]

50 (46)†
(2 wks to 16 wks)
duration 21 d

L reuteri

Daily crying time on day 21

Probiotics 35 min

Placebo 90 min*

Savino, 2007[43]

90 (83)
(21 days to 3 mos)
duration 28 d

L reuteri

1x108 CFU daily

versus simethicone

Daily crying time on day 28

Probiotic 51 min

Simethicone 145 min*

NS: non-significant, * : p < 0.05, † Brackets indicate final study population

Preventing necrotizing enterocolitis

Altered intestinal permeability and intestinal bacteria may be involved in the pathogenesis of necrotizing enterocolitis (NEC). One recent study showed that a bifidobacteria-supplemented formula decreased intestinal permeability in preterm infants.[45] Studies with NEC prevention as their primary outcome are listed in Table 6. In the first published study, LGG did not decrease the incidence of NEC significantly.[46] Subsequent studies showed that infants fed breast milk supplemented with lactobacillus and bifidobacteria had a significantly lower incidence of NEC and deaths than infants receiving unsupplemented breast milk.[47]-[49] The severity and incidence of NEC was lower in infants given a mixture of Bifidobacterium infantis, B bifidus and S thermophilus.[50]

In three recent meta-analyses, enteral probiotic supplementation significantly reduced the incidence of severe NEC (RR 0.32 to 0.36) and mortality (RR 0.40 to 0.47) without systemic infection with the bacteria used as probiotics.[51]-[53]

Probiotics may help to prevent NEC. Administering live microorganisms to preterm newborns should be approached with caution. Along with breastfeeding promotion, probiotics can be considered for the prevention of NEC in preterm infants >1 kg who are at risk for NEC. There is currently no data for infants weighing <1000 g.

Probiotic use in necrotizing enterocolitis (NEC)


Patients, age / weight,




Dani, 2002[46]

<33 wks and <1500 g


6x109 CFU daily

Probiotics 1.4%
Placebo 2.7% (NS)

Probiotics 4.4%
Placebo 3.8% (NS)

Lin, 2005[47]

<1500 g
Breast milk

L acidophilus
B infantis

125 mg/kg twice daily

NEC stage 2 or 3
Probiotics 1.1%
Placebo 5.3% *

Probiotics 3.9%
Placebo 10.7% *

Probiotics 12.2%
Placebo 19.3% *

Bin-Nun, 2005[50]

155 (145)
<1500 g

B infantis
B bifidus
S thermophilus

1x109 CFU daily

Probiotics 4%
Placebo 16.4%*

Lin, 2008[48]

< 1500 g and < 34 wks
Breast milk

B bifidus
L acidophilus

Probiotics 1.8 %
Placebo 9.2%*

Braga, 2011[49]

258 (231)
< 1500 g
Breast milk or mixed feeds

B breve
L casei

Probiotics 0%
Placebo 3.6%*

NS: non-significant, * : p < 0.05 CFU Colony forming unit

Traveller’s diarrhea

There are no paediatric studies of probiotics in preventing traveller’s diarrhea. A meta-analysis of adult trials showed a statistically significant protective effect for various probiotics (RR 0.85),[54] but most of these studies had significant limitations. No conclusions can be drawn from the literature at this time and further trials are needed.

Preventing infections

Probiotics may be useful in preventing infections, both by decreasing intestinal permeability and stimulating the immune system. In one Finnish study, children in day care centres who drank milk supplemented with LGG experienced fewer days with respiratory and gastrointestinal symptoms, but the only outcome to reach statistical significance was the number of days of absence due to illness.[23] B lactis and S thermophilus decreased antibiotic use significantly in children attending daycare.[55] Infant formulas supplemented with B lactis and L reuteri reduced the number of episodes of fever and diarrhea, the number of medical visits, the number of days absent from child care and antibiotic use[30] in one Israeli study. Finally, infants in one community who required formula feeding under two months of age were given LGG and B lactis Bb-12. These infants had a lower incidence of otitis media and recurrent respiratory infections, and were prescribed fewer antibiotics than others who received placebo[56](Table 7).

Probiotics might help to reduce childhood respiratory illnesses, antibiotic use and absences from child care due to illness. However, more trials are needed before any definitive conclusions can be made.

Probiotic use for preventing infections


Patients, setting, duration



Hatakka, 2001[23]

571 (513)†
(1 yr to 6 yrs)
duration 7 mos

5 – 10x105 CFU/mL of formula,
>200 mL daily

Days of absence due to illness
Probiotic 4.9 days
Placebo 5.8 days*

Days with respiratory symptoms
Probiotic 21
Placebo 23 (NS)

Antibiotic treatments
Probiotic 119
Placebo 144 (NS)

Saavedra, 2004[55]

131 (118)
(3 mos to 24 mos)
duration 210±127 days

B lactis
S thermophilus

Low dose (LD):
1x106 CFU of each/g

High dose (HD):
1x107 CFU of each/g

Days of absence due to illness
Probiotic LD 2.07 HD 1.86
Placebo 1.89 (NS)

Antibiotic treatments
Probiotics LD 2.47 HD 3.19
Placebo 3.60*

Weizman, 2005[30]

201 (194)
(4 mos to 10 mos)
child care centre
duration 12 wks

B lactis (Bb12)

L reuteri

1x107 CFU/g powder


Days of absence from daycare
B lactis 0.41 (NS)
L reuteri 0.14*
Placebo 0.43

Antibiotic treatments
B lactis 0.21 (NS)
L reuteri 0.06*
Placebo 0.19

Days with respiratory illness
B lactis 0.68 (NS)
L reuteri 0.38 (NS)
Placebo 0.60

Rautava, 2009[56]

(2 mos)
followed until 12 mos


B lactis (Bb12)

1x1010 CFU daily

Acute otitis media
Probiotic 22%
Placebo 50% *

Antibiotic treatment
Probiotics 31%
Placebo 60% *

Recurrent infections
Probiotics 28%
Placebo 55% *

NS: non-significant, * : p < 0.05, † Brackets indicate final study population

Preventing atopic and allergic diseases

Atopic diseases are often related to food allergies, which are more likely to develop when intestinal permeability is altered. Probiotics decrease intestinal permeability and the absorption of large molecules. This effect may help to prevent expression of an atopic constitution by diminishing allergen uptake. Lower counts of lactobacilli and bifidobacteria are found in children with atopic dermatitis compared with healthy controls.[57] In studies of children with atopic dermatitis treated with lactobacilli, a significant decrease in measures of intestinal permeability was observed, suggesting that impairments of gut barrier function in these patients can be improved with probiotics.[2] Also, gut microflora interact with gut-associated lymphoid tissue. Probiotics may influence the balance between the TH1 and TH2 responses and prevent the development of allergic disease.

Two RTCs suggested that LGG supplementation before delivery for pregnant mothers with a family history of atopy, and subsequent supplementation while breastfeeding or formula feeding later, reduced the risk of developing atopic dermatitis in their infants.[58]-[60] However, subsequent studies did not show such an effect.[61]-[64] A recent meta-analysis concluded that there was insufficient evidence to recommend adding probiotics to infant feeds to prevent allergic disease or food hypersensitivity [65] (Table 8).

Despite initially encouraging results, recent studies have failed to demonstrate a beneficial effect, and further research is required.

Probiotic use for preventing atopic disease





Kalliomaki, 2001[58]

Kalliomaki, 2003[59]

134 mother-infant pairs (at 2 yrs)

107 mother-infant pairs (at 4 yrs)

2 to 4 wks prenatally

24 wks postnatally


1x1010 twice daily

Atopic dermatitis at 2 yrs
Probiotic 23%
Placebo 46% *
RR 0.51, NTT 4.5

Atopic dermatitis at 4 yrs
Probiotic 26%
Placebo 46% *
RR 0.57

Rautava, 2002[60]

62 mother-infant pairs (57)†


2x1010 CFU daily

Atopic dermatitis in the first 2 yrs
Probiotic 15%
Placebo 47% *
RR 0.32

Kukkonen, 2007[63]

1223 mother-infant pairs (925)

2 to 4 wks prenatally

Mixture of four strains of probiotics and one prebiotic

No effect on allergic diseases
Reduction of atopic eczema
RR 0.66

Taylor, 2007[61]

231 newborns of mothers with allergies (178)

6 mos postnatally

L acidophilus

3x109 CFU daily

Atopic dermatitis at 6 mos
Probiotic 25.8%
Placebo 22.7% (NS)

Atopic dermatitis at 1 yr
Probiotic 43%
Placebo 39% (NS)

Abrahamsson, 2007[62]

232 mother-infant pairs with history of allergies (188)

4 wks prenatally

1 yr postnatally

L reuteri

1x108 CFU daily

Atopic dermatitis
Probiotic 36%
Placebo 34% (NS)

Positive skin prick test
Probiotic 14%
Placebo 31% *

Kopp, 2008 [64]

105 pregnant mothers with history of atopic disease (94)

4 to 6 wks prenatally

6 mos postnatally


5x109 CFU twice daily

Atopic dermatitis at 2 yrs
Probiotic 28%
Placebo 27.3% (NS)

NS: non-significant, * : p < 0.05, † Brackets indicate final study population

Treatment of atopic dermatitis

Two early probiotics studies showed promising results for the treatment of atopic dermatitis. LGG and L reuterii were used for six weeks in children with moderate to severe eczema. While there was no significant improvement in objective disease measurements, subjects on probiotics perceived significantly more improvement than those on placebo.[66] L fermentum also diminished atopic dermatitis scores.[67] However, three subsequent meta-analyses concluded that reductions in eczema severity from probiotic treatment were modest and unlikely to be clinically significant.[68]-[70]

Treatment of allergic colitis

Using LGG as an adjunct to maternal hypoallergenic diet in breastfed infants with rectal bleeding caused by allergic colitis did not significantly affect the duration of rectal bleeding.[71] One recent study suggested that there was a greater decrease in fecal calprotectin (a marker of intestinal inflammation) and that rectal bleeding disappeared more quickly in infants treated with extensively hydrolysed formula with probiotics than with extensively hydrolysed formula alone.[72]

Further studies are needed to draw conclusions at this point.

Side effects of probiotics

Some probiotics may cause systemic or local infections. LGG and saccharomyces sepsis have been described in critically ill or immunocompromised patients, in some immunocompetent patients, and in patients with a central venous catheter.[73]-[79] There have been no reports of bifidobacterial systemic infection, and there was no increase in the incidence of lactobacilli sepsis in Finland following their introduction of lactobacilli in dairy products. [80]


The literature suggests there are benefits to using probiotics for treating some diseases, such as AAD and acute infectious viral diarrhea, and to help prevent NEC. There might also be a beneficial effect in patients with colic and IBS. The role of probiotics remains unproven in preventing or treating atopic diseases. Caution should be exercised in giving probiotics to patients with an immunodeficiency. The efficacy of probiotics is both strain- and disease-specific, and any probiotic must be provided in adequate amount. Physicians need to be more aware of the differences among probiotic preparations, and government agencies should be involved in regulating the viability and composition of probiotic products.

Table 9 lists some probiotic products. No preparation of LGG is currently available in this country. A list of products licensed in Canada is available at:

Some probiotic products




Bio K + milk-based

L acidophilus
L casei

50 billion/container

Bio K + capsules

L acidophilus
L casei

50 billion/capsule

Probaclac children

B bifidum, B longum,
L acidophilus, L casei,
L bulgaricus, L rhamnosus
S thermophilus

3 billion/capsule

Florastor Kids

S boulardi

250 mg/packet

VSL # 3

B breve, B longum, B infantis,
L acidophilus, L plantarum,
L paracasei, L bulgaricus,
S thermophilus

450 billion/packet

Lactibiane Kids

(not available in Canada)


4 billion/packet

Culturelle Kids

(not available in Canada)


I billion/packet


L reuteri

Drops, straw, lozenge, ORS, chewable tablets, lifetop cap

ORS Oral rehydration solution


For physicians

1. Keeping in mind that the effect of probiotics is both strain- and disease-specific, physicians should consider recommending probiotics to:

  • prevent antibiotic-associated diarrhea.
  • shorten the duration of acute infectious viral diarrhea.
  • prevent necrotizing enterocolitis in preterm infants who are at risk of necrotizing enterocolitis.
  • decrease the symptoms of colic.
  • decrease some symptoms of irritable bowel syndrome.

2. Based on current evidence, the use of probiotics cannot yet be recommended for the treatment or prevention of atopic diseases.

3. Physicians should be aware of the small risks of invasive infections with using some strains of probiotics in immunocompromised patients, and more rarely in the healthy child.

4. Physicians should advocate for further research to define which strains and dose of probiotics should be used in specific conditions.

For government

The federal government should require manufacturers of probiotics and products containing probiotics to provide high quality products with precise and informative labelling.


This statement was reviewed by the Fetus and Newborn, and Infectious Diseases and Immunization Committees of the Canadian Paediatric Society.



Members: Dana L Boctor MD; Jeffrey N Critch MD(Chair); Manjula Gowrishankar MD; Daniel Roth MD; Sharon L Unger MD; Robin C Williams MD (Board Representative)
Liaisons: Jatinder Bhatia MD, American Academy of Pediatrics; Genevieve Courant NP, MSc, Breastfeeding Committee for Canada; A George F Davidson MD, Human Milk Banking Association; Tanis Fenton, Dietitians of Canada; Jennifer McCrea, Health Canada; Jae Hong Kim MD (Past member); Lynne Underhill MSc, Bureau of Nutritional Sciences, Health Canada
Principal author: Valérie Marchand MD (past Chair)



  1. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276(4 Pt 1):G941-50.
  2. Rosenfeldt V, Benfeldt E, Valerius NH, Paerregaard A, Michaelsen KF. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004;145(5):612-6.
  3. Cebra JJ, Periwal SB, Lee G, Lee F, Shroff KE. Development and maintenance of the gut-associated lymphoid tissue (GALT): The roles of enteric bacteria and viruses. Dev Immunol 1998;6(1-2):13-8.
  4. D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis. BMJ 2002;324(7350):1361.
  5. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21(5):583-90.
  6. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004;50(4):234-6.
  7. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135(5):564-8.
  8. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study. Pediatrics 1999;104(5):e64.
  9. Ruszczynski M, Radzikowski A, Szajewska H. Clinical trial: Effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther 2008;28(1):154-61.
  10. Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005;39(5):385-9.
  11. Jirapinyo P, Densupsoontorn N, Thamonsiri N, Wongarn R. Prevention of antibiotic-associated diarrhea in infants by probiotics. J Med Assoc Thai 2002;85 Suppl 2:S739-42.
  12. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP 1990;24(4):382-4.
  13. Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007(2);CD004827.
  14. Szajewska H, Ruszczy?ski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: A meta-analysis of randomized controlled trials. J Pediatr 2006;149(3):367-72.
  15. Conway S, Hart A, Clark A, Harvey I. Does eating yogurt prevent antibiotic-associated diarrhoea? A placebo-controlled randomised controlled trial in general practice. Br J Gen Pract 2007;57(545):953-9.
  16. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271(24):1913-8.
  17. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008(1);CD004611.
  18. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010(11);CD003048.
  19. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004(2);CD003048.
  20. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: A systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001;33 Suppl 2:S17-25.
  21. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: A meta-analysis. Dig Dis Sci 2002;47(11):2625-34.
  22. Van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: A meta-analysis. Pediatrics 2002;109(4):678-84.
  23. Hatakka K, Savilahti E, Pönkä A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: Double blind, randomised trial. BMJ 2001;322(7298):1327.
  24. Mastretta E, Longo P, Laccisaglia A, et al. Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr 2002;35(4):527-31.
  25. Oberhelman RA, Gilman RH, Sheen P, et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr 1999;134(1):15-20.
  26. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001;138(3):361-5.
  27. Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006;12(28):4557-60.
  28. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344(8929):1046-9.
  29. Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000;54(9):568-71.
  30. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents. Pediatrics 2005;115(1):5-9.
  31. Binns CW, Lee AH, Harding H, Gracey M, Barclay DV. The CUPDAY Study: Prebiotic-probiotic milk product in 1-3-year-old children attending childcare centres. Acta Paediatr 2007;96(11):1646-50.
  32. Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr 2004;39(2):147-52.
  33. Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with bifidobacterium lactis: Impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004;38(3):288-92.
  34. Chouraqui JP, Grathwohl D, Labaune JM, et al. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. Am J Clin Nutr 2008;87(5):1365-73.
  35. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14(17):2650-61.
  36. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15:15.
  37. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial. J Pediatr 2005;147(2):197-201.
  38. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25(2):177-184.
  39. Martens U, Enck P, Zieseniss E. Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci 2010;8:Doc07.
  40. Guandalini S, Magazz? G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;51(1):24-30.
  41. Savino F, Bailo E, Oggero R, et al. Bacterial counts of intestinal Lactobacillus species in infants with colic. Pediatr Allergy Immunol 2005;16(1):72-5.
  42. Savino F, Cresi F, Pautasso S,  et al. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr 2004;93(6):825-9.
  43. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: A prospective randomized study. Pediatrics 2007;119(1):e124-30.
  44. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. Pediatrics 2010;126(3):e526-33.
  45. Stratiki Z, Costalos C, Sevastiadou S, et al. The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants. Early Hum Dev 2007;83(9):575-9.
  46. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002;82(2):103-8.47.
  47. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005;115(1):1-4.
  48. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: A multicenter, randomized, controlled trial. Pediatrics 2008;122(4):693-700.
  49. Braga TD, da Silva GA, de Lira PI, de Carvalho Lima M. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: A double-blind, randomized, controlled trial. Am J Clin Nutr 2011;93(1):81-6.
  50. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005;147(2):192-6.
  51. Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011(3);CD005496.
  52. Alfaleh K, Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2008(1);CD005496.
  53. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: A systematic review of randomised controlled trials. Lancet 2007;369(9573):1614-20.
  54. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007;5(2):97-105.
  55. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: Tolerance and safety. Am J Clin Nutr 2004;79(2):261-7.
  56. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr 2009;101(11):1722-6.
  57. Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108(4):516-20.
  58. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. Lancet 2001;357(9262):1076-9.
  59. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361(9372):1869-71.
  60. Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109(1):119-21.
  61. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. J Allergy Clin Immunol 2007;119(1):184-91.
  62. Abrahamsson TR, Jakobsson T, Böttcher MF, et al. Probiotics in prevention of IgE-associated eczema: A double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2007;119(5):1174-80.
  63. Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007;119(1):192-8.
  64. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: No clinical effects of Lactobacillus GG supplementation. Pediatrics 2008;121(4):e850-6.
  65. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 2007(4);CD006475.
  66. Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111(2):389-95.
  67. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: A randomised controlled trial. Arch Dis Child 2005;90(9):892-7.
  68. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: A review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9(2):93-103.
  69. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008;121(1):116-21.
  70. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev 2008(4);CD006135.
  71. Szajewska H, Gawronska A, Wos H, Banaszkiewicz A, Grzybowska-Chlebowczyk U. Lack of effect of Lactobacillus GG in breast-fed infants with rectal bleeding: A pilot double-blind randomized controlled trial. J Pediatr Gastroenterol Nutr 2007;45(2):247-51.
  72. Baldassarre ME, Laforgia N, Fanelli M, Laneve A, Grosso R, Lifschitz C. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010;156(3):397-401.
  73. Patel R, Cockerill FR, Porayko MK, Osmon DR, Ilstrup DM, Keating MR. Lactobacillemia in liver transplant patients. Clin Infect Dis 1994;18(2):207-12.
  74. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004;38(4):457-8.
  75. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115(1):178-81.
  76. Lherm T, Monet C, Nougi?re B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28(6):797-801.
  77. Viggiano M, Badetti C, Bernini V, Garabedian M, Manelli JC. [Saccharomyces boulardii fungemia in a patient with severe burns – Article in French]. Ann Fr Anesth Reanim 1995;14(4):356-8.
  78. Pletincx M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21(1):113-5.
  79. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19(1):16-20.
  80. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002;35(1):1155-60.

Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.

Last updated: Apr 14 2015